Luspatercept diminishes the need for red blood cell replacement in transfusion-dependent β-thalassemia patients

A clinical decision report appraising: Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219-1231. https://doi.org/10.1056/NEJMoa1910182 for a patient with transfusion-dependent beta-thalassemia.